ABEO logo

ABEO Abeona Therapeutics Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.54
-1.63 (-39.09%)

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also featu…

Market Cap: $145.25Mwww.abeonatherapeutics.com

Price

No data yet.

Social Signal Score

44
5d
50
1 mentions
—
30d
40
6 mentions
—
60d
40
6 mentions
—
90d
44
14 mentions
—
news: 14

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 3Sell 0Strong Sell 0
Avg price target$17.67+595.7%
Low $15Median $17High $21
Current Consensus

Revenue

$13.49M+5169.92%
$-2.13M$3.08M$8.28M$13.49M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$1.15
$1.11–$1.18
2 analysts
FY2026
$-0.97-184% YoY
$-1.26–$-0.55
6 analysts
FY2027
$-0.18
$-1.00–$1.00
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Vishwas Seshadri
Sector
Healthcare
Industry
Biotechnology
Employees
226
Beta
1.30
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
2.96
www.abeonatherapeutics.com